Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. - Wikidata - wikimedia - TriplyDB

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.

http://www.wikidata.org/entity/Q33780411

about

A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.Treatment of relapsed Wilms tumors: lessons learned.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.

P2860

Q33405390-DDF46891-866A-49D4-A668-456783113E96 Q34352278-DDDDDD08-30D5-4E36-8AB3-64D8921E3FAB Q34725699-03766CD4-E1A2-458F-9143-D58B363881AC Q36467960-4B15AD4C-B62B-4485-A878-89A9C0CEC273 Q37642795-7713E6C0-C319-4A33-A77D-3566220BD057 Q38961012-2727F6AE-86C4-4020-8A7F-E30809937174 Q47133403-2DE444C9-16E7-4AF6-A51B-B7912F18EABE

P2860

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.

http://www.wikidata.org/entity/Q33780411

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase 1 study of an oxaliplati ...... s with recurrent solid tumors.

@ast

Phase 1 study of an oxaliplati ...... s with recurrent solid tumors.

@en

type

label

Phase 1 study of an oxaliplati ...... s with recurrent solid tumors.

@ast

Phase 1 study of an oxaliplati ...... s with recurrent solid tumors.

@en

prefLabel

Phase 1 study of an oxaliplati ...... s with recurrent solid tumors.

@ast

Phase 1 study of an oxaliplati ...... s with recurrent solid tumors.

@en

P1433

Q33780411-4C7C5580-47D2-4A65-8100-62687CEE265B

P1476

Q33780411-B328A429-F3A5-417C-81BA-6AAA1785257F

P2093

Q33780411-17D04B5F-291A-4C2B-802A-5AE9BFAFDB32

Q33780411-242ADD2F-576A-48A4-9645-C304FF19E9B9

Q33780411-45DED479-D4A4-46FD-8117-60A93FBF1211

Q33780411-C01DB6BD-6ED5-407B-9C5E-7BE33BAFBD32

Q33780411-D20D5B69-4E7E-4F01-B55F-2BAE601755E5

Q33780411-DA9DB273-A140-4E9F-B5CF-03E1001E5DC0

Q33780411-ECFCB44F-F679-42E5-B102-667F396E1325

Q33780411-F1DFD59F-4694-42E2-AE07-1ED34CEAB883

Q33780411-FCB564EA-4DFD-41BA-A0AD-47871FD9FB5E

P2860

Q33780411-01E73316-E9C9-4153-8CCE-0C99A7FC5920

Q33780411-02D1204A-431D-474E-8B25-8FE512F06EB3

Q33780411-09532D2C-AD28-4A74-A024-19F4DB065A29

Q33780411-0BE9A6D9-13FB-4152-983B-4E8F09DA9468

Q33780411-0C3D4652-E88A-4F69-B413-6531F7A4A80A

Q33780411-116DCA0C-F4CC-4311-84AE-F8483BAF0F89

Q33780411-1745AA85-3CE5-4F09-9FC8-3BAF3F275380

Q33780411-2C32128F-4EE9-4002-87D6-3A12DAEDB234

Q33780411-34F55579-E152-407C-81BF-C1875E209BB7

Q33780411-381D4637-A88E-421C-8AAD-E5584F95DC61

P304

Q33780411-D9248D8B-7423-40C1-BDAC-AA7D2DD99318

P31

Q33780411-269A93A0-E62C-4AF5-9BC1-448FE0A8A289

P356

Q33780411-C8598DBD-A8AD-4940-AC40-B236F7E59A18

P407

Q33780411-769263A3-EEFC-4B70-BA5B-66D630FF6299

P433

Q33780411-FECDA7C6-521E-4241-AC35-176ACD570C21

P478

Q33780411-E4039216-61D6-4ADC-B0FA-C6A7FD4EEDB4

P50

Q33780411-05950A75-689C-4277-8A9B-0C9CC50EEA05

P577

Q33780411-FD2449AD-4113-4FE5-910A-A885BE0C97BD

P5875

Q33780411-86F3D2B9-7D16-45BA-B982-54F51326A511

P698

Q33780411-515CE1EC-5912-42AA-B152-F705969FDB2A

P932

Q33780411-8DE2A5EB-CE78-40B0-B1B8-ABCFE0AE43F1

P356

P1433

P1476

Phase 1 study of an oxaliplati ...... s with recurrent solid tumors.

@en

P2093

Amy Watkins

http://www.w3.org/2001/XMLSchema#string

Clinton F Stewart

http://www.w3.org/2001/XMLSchema#string

Deborah A Ward

http://www.w3.org/2001/XMLSchema#string

Fred H Laningham

http://www.w3.org/2001/XMLSchema#string

Lisa M McGregor

http://www.w3.org/2001/XMLSchema#string

Percy Ivy

http://www.w3.org/2001/XMLSchema#string

Sheri L Spunt

http://www.w3.org/2001/XMLSchema#string

Victor M Santana

http://www.w3.org/2001/XMLSchema#string

Wayne L Furman

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice

Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: a Children's Cancer Group Study, CCG-9881.

Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.

Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study.

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study.

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.

High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors.

P304

655-664

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24054

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23714552

http://www.w3.org/2001/XMLSchema#string

P698

19117350

http://www.w3.org/2001/XMLSchema#string

P932

2852396

http://www.w3.org/2001/XMLSchema#string